Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020
Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020
复制标题
DOI：
10.1111/bjh.18597
复制
发表时间：
2022-12-13
影响因子：
6.5
通讯作者：
Kuittinen, Outi
中科院分区：
文献类型：
--
作者：
Harmanen, Minna;Hujo, Mika;Kuittinen, Outi
套细胞淋巴瘤（MCL）是一种罕见的外周b细胞淋巴瘤，其特征是最终复发并向更具侵袭性的疾病发展。随着以利妥昔单抗和阿糖胞苷为基础的免疫化疗方案的引入，该疾病的预后在过去二十年中发生了巨大变化。为了评估MCL患者的真实生存，我们使用了一个基于人群的队列，包括2000年至2020年间诊断和治疗的564名MCL患者。从七个芬兰治疗中心和一个西班牙治疗中心收集患者数据。对于整个患者群体，我们报告了2年总生存率（OS）为77%，5年总生存率为58%，10年总生存率为32%。估计中位生存期为诊断后80个月。在整个患者群体中，MCL与死亡率增加有关。此外，我们评估了MCL复发后患者的生存，目的是建立预后意义的分界点。根据我们对首次复发后生存期的统计分析，首次诊断后24个月内的疾病进展应被视为预后不良的有力指标。
Mantle cell lymphoma (MCL) is a rare peripheral B-cell lymphoma characterised by eventual relapse and progression towards a more aggressive disease biology. With the introduction of rituximab- and cytarabine-based immunochemotherapy regimens, the prognosis of the disease has changed dramatically over the last two decades. To assess the real-world survival of patients with MCL, we used a population-based cohort of 564 patients with MCL who were diagnosed and treated between 2000 and 2020. Patient data were collected from seven Finnish treatment centres and one Spanish treatment centre. For the entire patient population, we report a 2-year overall survival (OS) rate of 77%, a 5-year OS of 58%, and a 10-year OS of 32%. The estimated median OS was 80 months after diagnosis. MCL is associated with increased mortality across the entire patient population. Additionally, we assessed the survival of patients after MCL relapse with the aim of establishing a cut-off point of prognostic significance. Based on our statistical analysis of survival after the first relapse, disease progression within 24 months of the initial diagnosis should be considered as a strong indicator of poor prognosis.